Volume 20, Number 5—May 2014
Dispatch
Extensively Drug-Resistant Streptococcus pneumoniae, South Korea, 2011–2012
Table 2
Antimicrobial susceptibilities of 5 extensively drug-resistant Streptococcus pneumoniae isolates, Seoul, South Korea, 2011–2012*
Strain no. | MIC, μg/mL |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
LZD | TGC | VAN | PEN | TMP/SXT | CLI | CRO | LVX | ERY | CLR | TET | IPM | |
SMC1101–114 | 0.5 | <0.03 | 0.5 | 8 | 32/608 | >32 | 16 | 16 | 64 | 16 | 32 | 2 |
SMC1101–127 | 0.5 | <0.03 | 0.25 | 8 | 32/608 | >32 | 64 | 16 | 128 | >32 | 32 | 2 |
SMC1103–146 | 0.5 | <0.03 | 0.25 | 8 | 32/608 | >32 | 64 | 16 | 128 | >32 | 32 | 2 |
SMC1105–235 | 0.5 | <0.03 | 0.25 | 8 | 32/608 | >32 | 32 | 16 | 128 | >32 | 32 | 2 |
SMC1108–054 | 0.5 | <0.03 | 0.5 | 8 | 32/608 | >32 | 64 | 16 | 128 | >32 | 16 | 2 |
*LZD, linezolid; TGC, tigecycline; VAN, vancomycin; PEN, penicillin; TMP/SXT, trimethoprim/sulfamethoxazole; CLI, clindamycin;
CRO, ceftriaxone; LVX, levofloxacin; ERY, erythromycin; CLR, clarithromycin; TET, tetracycline; IPM, imipenem; SMC, Samsung Medical Center.
1These authors contributed equally to this article.
Page created: April 17, 2014
Page updated: April 17, 2014
Page reviewed: April 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.